Posted On: 12/28/2015 11:13:13 AM
Post# of 72444
Re: scottsmith #16968
looking at CMRX disaster today, down 80%, makes me even more glad that we have THREE completely different drugs for 4 indications in clinical trials.
Don't know if CRMX can survive failure of their lead drug. They're focused on anti-virals. Eggs in one basket, and the basket broke.
EDIT: even after this failure, their market cap is 349 million, much more than CTIX's. That tells you what a bargain CTIX is.
Don't know if CRMX can survive failure of their lead drug. They're focused on anti-virals. Eggs in one basket, and the basket broke.
EDIT: even after this failure, their market cap is 349 million, much more than CTIX's. That tells you what a bargain CTIX is.
(0)
(0)Scroll down for more posts ▼
